Use of Direct-acting Antiviral to Treat HCV Recurrence After Liver Transplantation (ANRSCO23CUPILT) Infection

Cohort of Liver Transplanted Patients With Hepatitis C Virus Recurrence and Treated With Direct-acting Antiviral Agents

The purpose of this study is to evaluate the efficacy, safety and tolerability of direct-acting antivirals therapy in liver transplanted patients who experienced HCV recurrence.

This cohort is multicentric with constitution of biobank (plasma, serum) and the prospective collect of biological and clinical data's in the liver transplanted patients with recurrent HCV infection and treated with direct-acting anti-HCV agents.

Inclusion Criteria:

• Age > 18 years-old
• Liver transplanted patient
• Hepatitis C virus infection before transplantation
• HCV recurrence with a detectable HCV RNA before enrollment in cohort
• Use of at least one direct-acting antiviral agents with or without association with peginterferon and with or without association with ribavirin
• Treated by direct-acting antiviral agents or has been yet completed the treatment but still on follow up
• Affiliated to Health Insurance
• Written Signed consent form

Exclusion Criteria:

• Pregnant or breast-feeding female